Literature DB >> 15139002

Genomic aberrations in carcinomas of the uterine corpus.

Francesca Micci1, Manuel R Teixeira, Lisbeth Haugom, Gunnar Kristensen, Vera M Abeler, Sverre Heim.   

Abstract

Endometrial carcinoma, the most common invasive neoplasm of the female genital tract, occurs either in a hormone-related, less virulent form (type I) or in a hormone-independent, more aggressive form (type II). Another cancer of the uterine corpus is carcinosarcoma, a biphasic or mixed epithelial-mesenchymal tumor, now classified as metaplastic carcinoma. We examined by karyotyping and comparative genomic hybridization a consecutive series of 67 endometrial carcinomas and 15 carcinosarcomas and compared the cytogenetic features of the different carcinoma subtypes. All three subtypes of uterine carcinoma had in common a nonrandom gain of material from 1q and 8q but differed from one another in other respects. Endometrial carcinomas of type I mostly presented gains from chromosome arms 1q and 8q and losses from Xp, 9p, 9q, 17p, 19p, and 19q, whereas endometrial carcinomas of type II showed a more complex imbalance picture, with gains from chromosome arms 1q, 2p, 3q, 5p, 6p, 7p, 8q, 10q, and 20q and losses from Xq, 5q, and 17p. The carcinosarcomas mostly showed gains of or from 1q, 5p, 8q, and 12q but losses from 9q, that is, they were much more similar to endometrial carcinomas in their pattern of acquired genomic changes than to sarcomas of the uterine corpus. It was also possible to identify different copy number changes among the different grades of type I carcinomas, between serous papillary and clear-cell carcinomas of type II, as well as between homologous and heterologous carcinosarcomas. Specifically, type I adenocarcinomas that were highly differentiated mostly showed gains from 1q and 10p; those that were moderately differentiated showed gains from 1q, 7p, 7q, and 10q as well as losses from Xp, 9p, 9q, 17p, 19p, and 19q; whereas those poorly differentiated showed gains from 1q, 2p, 2q, 3q, 6p, 8q, and 20q but losses from Xp, Xq, 5q, 9p, 9q, 17p, and 17q. The serous papillary carcinomas showed gains from 1q, 2p, 2q, 3q, 5p, 6p, 6q, 7p, 8q, 18q, 20p, and 20q but losses from 17p, whereas the clear-cell carcinomas showed gains from 3q, 7p, 8q, 10q, 16p, and 20q but losses from 6q. Finally, the homologous carcinosarcomas presented gains from 1p, 1q, 8q, 12q, and 17q as well as losses from 9q and 13q, whereas the heterologous tumors showed gains from 1q, 8p, and 8q. The reproducibility of the observed correlations between karyotypic aberration patterns and histological differentiation was underscored by the fact that those carcinosarcomas whose epithelial component resembled type I endometrial carcinomas also exhibiting a type I aberration profile, whereas carcinosarcomas with a type II carcinoma differentiation had karyotypic abnormalities similar to those of type II endometrial carcinomas. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15139002     DOI: 10.1002/gcc.20038

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  21 in total

1.  Genomic imbalances in endometrial adenocarcinomas - comparison of DNA ploidy, karyotyping and comparative genomic hybridization.

Authors:  Wanja Kildal; Francesca Micci; Bjørn Risberg; Vera M Abeler; Gunnar B Kristensen; Sverre Heim; Håvard E Danielsen
Journal:  Mol Oncol       Date:  2011-10-20       Impact factor: 6.603

Review 2.  Clear cell carcinoma of ovary and uterus.

Authors:  Rosalind M Glasspool; Iain A McNeish
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

3.  Genomic aberrations in borderline ovarian tumors.

Authors:  Francesca Micci; Lisbeth Haugom; Terje Ahlquist; Hege K Andersen; Vera M Abeler; Ben Davidson; Claes G Trope; Ragnhild A Lothe; Sverre Heim
Journal:  J Transl Med       Date:  2010-02-26       Impact factor: 5.531

4.  The genomics and genetics of endometrial cancer.

Authors:  Andrea J O'Hara; Daphne W Bell
Journal:  Adv Genomics Genet       Date:  2012-03

5.  Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma.

Authors:  Eric J Devor; Jillian N DE Mik; Shyam Ramachandran; Michael J Goodheart; Kimberly K Leslie
Journal:  Exp Ther Med       Date:  2012-01-25       Impact factor: 2.447

6.  Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation.

Authors:  H B Salvesen; S L Carter; M Mannelqvist; A Dutt; G Getz; I M Stefansson; M B Raeder; M L Sos; I B Engelsen; J Trovik; E Wik; H Greulich; T H Bø; I Jonassen; R K Thomas; T Zander; L A Garraway; A M Oyan; W R Sellers; K H Kalland; M Meyerson; L A Akslen; R Beroukhim
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-04       Impact factor: 11.205

7.  Differential roles of telomere attrition in type I and II endometrial carcinogenesis.

Authors:  Esra A Akbay; Cristina M Contreras; Samanthi A Perera; James P Sullivan; Russell R Broaddus; John O Schorge; Raheela Ashfaq; Hossein Saboorian; Kwok-Kin Wong; Diego H Castrillon
Journal:  Am J Pathol       Date:  2008-07-03       Impact factor: 4.307

8.  A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.

Authors:  Susana M Campos; William E Brady; Katherine M Moxley; Roisin E O'Cearbhaill; Paula S Lee; Paul A DiSilvestro; Jacob Rotmensch; Peter G Rose; Premal H Thaker; David M O'Malley; Parviz Hanjani; Rosemary E Zuna; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2014-03-01       Impact factor: 5.482

9.  Tumor spreading to the contralateral ovary in bilateral ovarian carcinoma is a late event in clonal evolution.

Authors:  Francesca Micci; Lisbeth Haugom; Terje Ahlquist; Vera M Abeler; Claes G Trope; Ragnhild A Lothe; Sverre Heim
Journal:  J Oncol       Date:  2009-09-15       Impact factor: 4.375

10.  S100A4 mediates endometrial cancer invasion and is a target of TGF-beta1 signaling.

Authors:  Ran Xie; Matthew P Schlumbrecht; Gregory L Shipley; Susu Xie; Roland L Bassett; Russell R Broaddus
Journal:  Lab Invest       Date:  2009-06-08       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.